- Lobbying
- Lobbying by Greenwich Biosciences, Inc.
Lobbying Relationship
Bills mentioned
H.R.3797: Medical Marijuana Research Act
Sponsor: Earl Blumenauer (D-Ore.)
H.R.841: Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization...
Sponsor: Kurt Schrader (D-Ore.)
S.4348: FDASLA Act of 2022
Sponsor: Patty Murray (D-Wash.)
H.R.2617: Consolidated Appropriations Act, 2023
Sponsor: Gerald E. Connolly (D-Va.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Wade Ackerman | Sr. FDA Counsel, U.S. Senate Committee on Health, Education, Labor & Pensions |
Gary Heimberg | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate